{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:41:27Z","timestamp":1789159287907,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00417-025-07053-8","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:57:11Z","timestamp":1768010231000},"page":"983-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of macular neovascularization development on geographic atrophy progression"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-2461","authenticated-orcid":false,"given":"Mariano","family":"Cozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-1208","authenticated-orcid":false,"given":"Matteo","family":"Airaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-5251","authenticated-orcid":false,"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-5500","authenticated-orcid":false,"given":"Federico","family":"Corvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"7053_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013116","journal-title":"Lancet Glob Health"},{"key":"7053_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024) Age-related macular degeneration: a review. JAMA 331:147\u2013157","journal-title":"JAMA"},{"key":"7053_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B et al (2018) Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 125:878\u2013886","journal-title":"Ophthalmology"},{"issue":"12","key":"7053_CR4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","volume":"127","author":"KL Spooner","year":"2020","unstructured":"Spooner KL, Fraser-Bell S, Cozzi M et al (2020) Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors Using a Treat-and-Extend or a Pro-Re-Nata Regimen. Four Year Results of the MANEX Study. Ophthalmology 127(12):1663\u20131673","journal-title":"Ophthalmology"},{"key":"7053_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00417-020-04821-6","volume":"259","author":"F Corvi","year":"2021","unstructured":"Corvi F, Cozzi M, Invernizzi A et al (2021) Opticalcoherence tomography angiography for detection of macular neovascularization associated withatrophy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 259:291\u2013299. https:\/\/doi.org\/10.1007\/s00417-020-04821-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7053_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ophtha.2021.02.023","volume":"128","author":"M Cozzi","year":"2021","unstructured":"Cozzi M, Airaldi M, Invernizzi A (2021) OCT angiography reveals bilateral macular neovascularization encircling macular atrophy. Ophthalmology 128:1275","journal-title":"Ophthalmology"},{"key":"7053_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1136\/bjophthalmol-2021-318820","volume":"106","author":"R Sacconi","year":"2022","unstructured":"Sacconi R, Brambati M, Miere A et al (2022) Characterisation of macular neovascularisation in geographic atrophy. Br J Ophthalmol 106:1282\u20131287","journal-title":"Br J Ophthalmol"},{"issue":"22","key":"7053_CR8","first-page":"00189","volume":"S2468\u20136530","author":"M Airaldi","year":"2022","unstructured":"Airaldi M, Corvi F, Cozzi M et al (2022) Differences in long-term progression of atrophy between neovascular and non-neovascular age-related macular degeneration. Ophthalmol Retina S2468\u20136530(22):00189\u201300180","journal-title":"Ophthalmol Retina"},{"key":"7053_CR9","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s00417-023-06168-0","volume":"261","author":"S Blazaki","year":"2023","unstructured":"Blazaki S, Blavakis E, Chlouverakis G et al (2023) Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes. Graefes Arch Clin Exp Ophthalmol 261:3425\u20133436","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7053_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","volume":"4","author":"M Pfau","year":"2020","unstructured":"Pfau M, M\u00f6ller PT, K\u00fcnzel SH et al (2020) Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmol Retina 4:238\u2013248","journal-title":"Ophthalmol Retina"},{"key":"7053_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ophtha.2020.01.040","volume":"127","author":"L Chen","year":"2020","unstructured":"Chen L, Messinger JD, Sloan KR et al (2020) Nonexudative macular neovascularization supporting outer retina in Age-Related macular degeneration: A clinicopathologic correlation. Ophthalmology 127:931\u2013947","journal-title":"Ophthalmology"},{"key":"7053_CR12","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.8.8","volume":"9","author":"L Chen","year":"2020","unstructured":"Chen L, Li M, Messinger JD et al (2020) Recognizing atrophy and mixed-type neovascularization in age-related macular degeneration via clinicopathologic correlation. Transl Vis Sci Technol 9:8","journal-title":"Transl Vis Sci Technol"},{"key":"7053_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.oret.2020.10.008","volume":"5","author":"CK Hwang","year":"2021","unstructured":"Hwang CK, Agr\u00f3n E, Domalpally A et al (2021) Progression of geographic atrophy with subsequent exudative neovascular disease in age-related macular degeneration: AREDS2 report 24. Ophthalmol Retina 5:108\u2013117","journal-title":"Ophthalmol Retina"},{"key":"7053_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG et al (2018) Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology 125:537\u2013548","journal-title":"Ophthalmology"},{"key":"7053_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.oret.2018.10.012","volume":"3","author":"Y Shi","year":"2019","unstructured":"Shi Y, Motulsky EH, Goldhardt R et al (2019) Predictive value of the OCT double-layer sign for identifying subclinical neovascularization in age-related macular degeneration. Ophthalmol Retina 3:211\u2013219","journal-title":"Ophthalmol Retina"},{"key":"7053_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.oret.2023.10.006","volume":"8","author":"L Csincsik","year":"2024","unstructured":"Csincsik L, Muldrew KA, Bettiol A et al (2024) The double layer sign is highly predictive of progression to exudation in age-related macular degeneration. Ophthalmol Retina 8:234\u2013245","journal-title":"Ophthalmol Retina"},{"key":"7053_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","volume":"131","author":"WJ Feuer","year":"2013","unstructured":"Feuer WJ, Yehoshua Z, Gregori G et al (2013) Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26. JAMA Ophthalmol 131:110\u2013111","journal-title":"JAMA Ophthalmol"},{"key":"7053_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","volume":"143","author":"FG Holz","year":"2007","unstructured":"Holz FG, Bindewald-Wittich A, Fleckenstein M et al (2007) Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 143:463\u2013472","journal-title":"Am J Ophthalmol"},{"key":"7053_CR19","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/bjophthalmol-2021-320047","volume":"107","author":"F Corvi","year":"2023","unstructured":"Corvi F, Bacci T, Corradetti G et al (2023) Characterisation of the vascular anterior surface of type 1 macular neovascularisation after anti-VEGF therapy. Br J Ophthalmol 107:1336\u20131343","journal-title":"Br J Ophthalmol"},{"key":"7053_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/IAE.0000000000002842","volume":"41","author":"D Cabral","year":"2021","unstructured":"Cabral D, Coscas F, Pereira T, IMPLICATIONS OF THE MORPHOLOGIC PATTERNS OF TYPE 1 MACULAR NEOVASCULARIZATION ON MACULAR ATROPHY GROWTH ON PATIENTS UNDER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT et al (2021) Retina 41:287\u2013295","journal-title":"Retina"},{"key":"7053_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1167\/iovs.66.11.16","volume":"66","author":"S Fragiotta","year":"2025","unstructured":"Fragiotta S, Parravano M, Sacconi R et al (2025) Progression patterns in foveal-sparing geographic atrophy with double-layer sign due to neovascularization or basal laminar deposits. Invest Ophthalmol Vis Sci 66:16","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7053_CR22","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G et al (2023) Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402:1449\u20131458","journal-title":"Lancet"},{"key":"7053_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.oret.2018.01.019","volume":"2","author":"L Shen","year":"2018","unstructured":"Shen L, Liu F, Grossetta Nardini H, Del Priore LV (2018) Natural history of geographic atrophy in untreated eyes with nonexudative age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Retina 2:914\u2013921","journal-title":"Ophthalmol Retina"},{"key":"7053_CR24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","volume":"125","author":"TD Keenan","year":"2018","unstructured":"Keenan TD, Agr\u00f3n E, Domalpally A et al (2018) Progression of geographic atrophy in Age-related macular degeneration: AREDS2 report number 16. Ophthalmology 125:1913\u20131928","journal-title":"Ophthalmology"},{"key":"7053_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","volume":"136","author":"FG Holz","year":"2018","unstructured":"Holz FG, Sadda SR, Busbee B et al (2018) Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 136:666\u2013677","journal-title":"JAMA Ophthalmol"},{"key":"7053_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1167\/iovs.63.1.20","volume":"63","author":"O Trivizki","year":"2022","unstructured":"Trivizki O, Moult EM, Wang L et al (2022) Local geographic atrophy growth rates not influenced by close proximity to non-exudative type 1 macular neovascularization. Invest Ophthalmol Vis Sci 63:20","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7053_CR27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.5.10","volume":"63","author":"M Pfau","year":"2022","unstructured":"Pfau M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2022) Re: trivizki et al. local geographic atrophy growth rates not influenced by close proximity to non-exudative type 1 macular neovascularization. Invest Ophthalmol Vis Sci 63:10","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7053_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.63.5.11","volume":"63","author":"O Trivizki","year":"2022","unstructured":"Trivizki O, Moult EM, Wang L et al (2022) Author response: local geographic atrophy growth rates not influenced by close proximity to non-exudative type 1 macular neovascularization. Invest Ophthalmol Vis Sci 63:11","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7053_CR29","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.neurobiolaging.2014.05.003","volume":"35","author":"A Biesemeier","year":"2014","unstructured":"Biesemeier A, Taubitz T, Julien S et al (2014) Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35:2562\u20132573","journal-title":"Neurobiol Aging"},{"key":"7053_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.oret.2019.01.024","volume":"3","author":"M Thulliez","year":"2019","unstructured":"Thulliez M, Zhang Q, Shi Y et al (2019) Correlations between choriocapillaris flow deficits around geographic atrophy and enlargement rates based on swept-source OCT imaging. Ophthalmol Retina 3:478\u2013488","journal-title":"Ophthalmol Retina"},{"key":"7053_CR31","unstructured":"Alexion Pharmaceuticals IA, Phase D-M (2024) Placebo-controlled, dose range finding study of danicopan (ALXN2040) in patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). ClinicalTrials.gov Identifier: NCT05019521"},{"key":"7053_CR32","unstructured":"Janssen R, Development LLCA, Phase 2b, Randomized (2024) Double-masked, Multicenter, dose-ranging, sham-controlled clinical trial to evaluate intravitreal JNJ-81201887 (AAVCAGsCD59) compared to sham procedure for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). clinicaltrials.gov"},{"key":"7053_CR33","unstructured":"Aviceda Therapeutics (2024) Inc. A single and multiple dose study to evaluate Safety, Pharmacokinetics, and treatment effect of intravitreal AVD-104 in participants with geographic atrophy secondary to Age-related macular degeneration. clinicaltrials.gov"},{"key":"7053_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG et al (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402:1434\u20131448","journal-title":"Lancet"},{"key":"7053_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.oret.2022.11.002","volume":"7","author":"G Staurenghi","year":"2023","unstructured":"Staurenghi G, Cozzi M, Sadda S et al (2023) Characteristics that correlate with macular atrophy in ranibizumab-treated patients with neovascular age-related macular degeneration. Ophthalmol Retina 7:300\u2013306","journal-title":"Ophthalmol Retina"},{"key":"7053_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2017.08.019","volume":"125","author":"M Li","year":"2018","unstructured":"Li M, Dolz-Marco R, Messinger JD et al (2018) Clinicopathologic correlation of anti-vascular endothelial growth factor-treated type 3 neovascularization in age-related macular degeneration. Ophthalmology 125:276\u2013287","journal-title":"Ophthalmology"},{"key":"7053_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology 127:616\u2013636","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07053-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:37:02Z","timestamp":1773909422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07053-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7053"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07053-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Milan and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Given the retrospective design of the study, the need for informed consent was waived by the local Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr Airaldi, Dr Barbieri and Dr. Corvi have no financial disclosures. Dr. Cozzi has the following financial disclosures: Bayer (Recipient), Nidek (Recipient), Novartis (Recipient), Zeiss (Recipient), Heidelberg Engineering (Recipient). Dr. Sadda has the following financial disclosures: Consulting fees: Amgen, Abbvie\/Allergan, Alnylam, CharacterBio, Bayer, Regeneron, Roche\/Genentech, Novartis, ONL Tx, Ocular Tx, Eyepoint, Jannsen Iveric, Apellis, Alexion, Nanoscope, 4DMT, Optos, Heidelberg, and iCare; Research instruments outside the submitted work: Intalight, Topcon, Nidek, Heidelberg, iCare, Optos, and Carl Zeiss Meditec. Dr. Staurenghi has the following financial disclosures: Heidelberg Engineering (Consultant), Optos (Financial Support), Ocular Instruments (Patent), OptoVue (Financial Support), CenterVue (Consultant), Allergan (Consultant), Bayer (Consultant), Genetech (Consultant), Novartis (Consultant), Quantel Medical (Consultant), Carl Zeiss Meditec (Consultant), Appellis (Consultant), Boheringer (Consultant), Topcon (Financial Support), Roche (Consultant).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}